NGHIÊN CỨU ĐÁNH GIÁ ĐÁP ỨNG MIỄN DỊCH SAU TIÊM VẮC XIN PHÒNG COVID-19 CỦA OXFORD-ASTRAZENECA BẰNG HAI PHƯƠNG PHÁP XÉT NGHIỆM PHÁT HIỆN KHÁNG THỂ IgG KHÁNG PROTEIN S CỦA SARS-COV-2 VÀ KHÁNG THỂ TRUNG HÒA VI RÚT
Viện Y sinh Nhiệt đới, Trung tâm Nhiệt đới Việt - Nga
Số 63 Nguyễn Văn Huyên, Nghĩa Đô, Cầu Giấy, Hà Nội
Số điện thoại: 0383079588; Email: viethuongk61@gmail.com
Nội dung chính của bài viết
Tóm tắt
STUDY TO EVALUATE THE IMMUNE RESPONSE AFTER VACCINATION AGAINST COVID-19 OF OXFORD-ASTRAZENECA BY TWO METHODS TO DETECT IgG ANTIBODIES AGAINST PROTEIN S OF SARS-COV-2 AND NEUTRALIZING ANTIBODIES
SARS-CoV-2 is a dangerous pandemic affecting humanity from 2019 to the present. Currently, there is no specific treatment for the disease caused by SARS-CoV-2 virus. Therefore, vaccines are an effective method to control and prevent diseases. To assess the immune response following vaccination against COVID-19, Anti-SARS-CoV-2 IgG antibody and neutralizing antibodies levels were measured in 50 volunteers aged 18 to 69, at the time before vaccination including; 28 days after the first dose, 28 days and 6 months after the 2nd dose of Oxford-AstraZeneca vaccine. In this analysis, IgG antibody was detected in all samples at 28 days after the first dose of vaccine, the geometric mean IgG levels were 229.3± 155.9 IU/ml. The aniti-spike IgG leved peaked 28 days of the second dose vaccination: the mean IgG levels were 800.3± 991.3 IU/ml. After 6 months from the day of the second injection, IgG level was 297.7± 299.2 IU/ml. The highest level of neutralizing antibodies (NAbs) was also at 28 days after the second injection with the average value 686.7± 466.8 IU/ml. After 6 months of the second injection, the NAbs level remained 275.8± 246.2 IU/ml. Thus, after receiving two doses of the vaccine, 98% of the study participants produced antibodies specific to SARS-CoV-2 and maintained antibodies after 6 months.
Từ khóa
COVID-19, IgG antibodies, neutralizing antibodies, vaccine, mmunogenicity, kháng thể IgG, kháng thể trung hòa, đáp ứng miễn dịch
Chi tiết bài viết
Tài liệu tham khảo
2. World Trade Organization. Coronavirus disease (COVID-19) Weekly
epidemiological update and weekly operational update, 2021, Available online at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/ situation-reports.
3. Eibagoury M., Tolba M. M., Nasser H. A., Jabbar A., Elagouz A. M., Aktham Y., Amy Hutchinson, The find of COVID-19 vaccine: challenges and opportunities., J. Infect. Public Health, 2021, 14:389-416.
4. Moghadas S. M., Vilches T. N., Zhang K., Wells C. R., Shoukat A., Singer B. H., Meyers L. A., Neuzil K. M., Langley J. M., Fitzpatrick M. C., Galvani A. P., The impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States, Clinical Infectious Diseases, 2021, 73(12):2257-2264.
5. Ali Roghani, The relationship between macro-socioeconomics determinants and COVID-19 vaccine distribution, AIMS Public Health, 2021, 8(4):655-664.
6. Noa Dagan M. D., Noam Barda M. D., Eldad Kepten Ph. D., Oren Miron M. A., Shay Perchik M. A., Mark A., Katz M. D., Miguel A., Hernán M. D., Marc Lipsitch D., Phil., Ben Reis Ph. D., Ran D., Balicer M. D., BNT162b2 mrna COVID-19 vaccine in a nationwide mass vaccination setting, The New England Journal Medicine, 2021, 384:1412-23.
7. WHO-2019-nCoV-vaccines-sage-recommendation-azd1222-2021.3-eng.pdf.
8. Ling Ni, et al., Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals, Immunity, 2020, 52(6):971-977.
9. Jiang S., Hillyer C., Du L., Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses, Trends Immunol., 2020, 41(5):355-359.
10. Grzelak L., Temmam S., Planchais C., Demeret C., Tondeur L., Huon C., Guivel-Benhassine F., Staropoli I., Chazal M., Dufloo J., et al., A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations, Science Translational Medicine, 2020, 12(59):1-13.
11.https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1003840/cma_ukpar_COVID_19_vaccine_astrazeneca_par_16.07.2021.pdf.
12. Louise J., Robertsona M., Andrew Nesbita James A. D., McLaughlincd, IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination: A Northern Ireland observational study, ScienceDirect, 2022 40(18):2535-2539.
13. Nguyen Van Vinh Chau, et al., Immunogenicity of oxford-astrazeneca covid-19 vaccine in vietnamese health-care workers, The American Journal of Tropical Medicine and Hygiene, 2022, 106(2):556-561.